Decoding innate immune signaling in normal and myelodysplastic hematopoiesis
解码正常和骨髓增生异常造血中的先天免疫信号
基本信息
- 批准号:10571337
- 负责人:
- 金额:$ 111.3万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-01-01 至 2029-12-31
- 项目状态:未结题
- 来源:
- 关键词:Acute leukemiaAge YearsAutomobile DrivingBasic ScienceBlood CellsBone MarrowCardiovascular DiseasesCellsChronicCollectionDevelopmentDiseaseDysmyelopoietic SyndromesElderlyFailureGeneticHematological DiseaseHematopoiesisHematopoietic stem cellsHereditary DiseaseImmuneImmune signalingIncidenceIndividualInflammationInflammatoryKnowledgeLife ExpectancyModalityModelingMolecularPathogenesisPatientsPharmacotherapyPhenotypeResearchSignal PathwaySyndromeTestingeffective therapyinnate immune functioninnate immune pathwaysknowledge of resultsmouse modelnew therapeutic targetnovelnovel therapeutic interventionprogramstherapeutic targettooltreatment strategy
项目摘要
Abstract
Myelodysplastic Syndromes (MDS) are heterogenous and poorly understood hematopoietic stem cell
(HSC) failure syndromes common in individuals >60 years of age. With increased life expectancies, the
incidence of MDS continues to rise, and will soon be the most prevalent hematologic disorder in elderly.
There are no effective treatments for MDS patients, due to an insufficient understanding of the underlying
pathobiology and a lack of faithful mouse models. Our research program is focused on filling these gaps,
and then leveraging the resulting knowledge and tools to develop effective drug therapies. Already, we
have discovered genetically-driven aberrant activation of innate immune pathways in MDS HSCs. We
have also identified a critical function of innate immune pathways in normal HSCs, which has
implications for chronic immune-related disorders, cardiovascular diseases, and hematopoiesis. We
hypothesize that dysregulated innate immune signaling is a major contributor to the initiation and
development of MDS, and is a feasible therapeutic target. Herein, we propose to test this hypothesis by
carrying out the following complimentary 3-part research program: (1) Dissect the genetic and cellular
underpinnings of MDS HSCs, with an emphasis on cell-intrinsic and cell-extrinsic immune-inflammatory
factors. (2) Identify and characterize novel signaling pathways driving MDS phenotype in HSCs. (3)
Develop novel therapeutic strategies for the treatment of MDS. The results of our research program will
advance our paradigm-shifting model of the initiation, progression, and treatment of MDS.
摘要
骨髓增生异常综合征(MDS)是一种异质性造血干细胞,
(HSC)在>60岁的个体中常见的失败综合征。随着预期寿命的增加,
MDS的发病率持续上升,并将很快成为老年人中最普遍的血液病。
由于对MDS患者的基础疾病认识不足,
病理生物学和缺乏可靠的小鼠模型。我们的研究计划专注于填补这些空白,
然后利用由此产生的知识和工具来开发有效的药物疗法。已经,我们
已经发现了MDS HSC中先天免疫途径的遗传驱动的异常激活。我们
还确定了正常HSC中先天免疫途径的关键功能,
对慢性免疫相关疾病、心血管疾病和造血的影响。我们
假设先天性免疫信号传导失调是引发免疫缺陷的主要因素,
MDS的发展,并且是可行的治疗靶点。在此,我们建议通过以下方式来检验这一假设:
进行以下三部分的研究计划:(1)解剖遗传和细胞
MDS HSC的基础,重点是细胞内源性和细胞外源性免疫炎症
因素(2)鉴定和表征HSC中驱动MDS表型的新型信号通路。(三)
开发治疗MDS的新治疗策略。我们的研究计划的结果将
推进我们的MDS的启动,进展和治疗的范式转变模型。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Daniel Starczynowski其他文献
Daniel Starczynowski的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Daniel Starczynowski', 18)}}的其他基金
Cincinnati Cooperative Center of Excellence in Hematology
辛辛那提血液学卓越合作中心
- 批准号:
10201885 - 财政年份:2021
- 资助金额:
$ 111.3万 - 项目类别:
Cincinnati Cooperative Center of Excellence in Hematology
辛辛那提血液学卓越合作中心
- 批准号:
10673643 - 财政年份:2021
- 资助金额:
$ 111.3万 - 项目类别:
Cincinnati Cooperative Center of Excellence in Hematology
辛辛那提血液学卓越合作中心
- 批准号:
10458590 - 财政年份:2021
- 资助金额:
$ 111.3万 - 项目类别:
Targeting IRAK1/4 in Myelodysplastic Syndromes
靶向治疗骨髓增生异常综合征中的 IRAK1/4
- 批准号:
9301788 - 财政年份:2017
- 资助金额:
$ 111.3万 - 项目类别:
Decoding innate immune signaling in normal and myelodysplastic hematopoiesis
解码正常和骨髓增生异常造血中的先天免疫信号
- 批准号:
10347307 - 财政年份:2017
- 资助金额:
$ 111.3万 - 项目类别:
相似海外基金
PREDICTING CARIES RISK IN UNDERSERVED CHILDREN, FROM TODDLERS TO THE SCHOOL-AGE YEARS, IN PRIMARY HEALTHCARE SETTINGS
预测初级医疗保健机构中从幼儿到学龄儿童的龋齿风险
- 批准号:
10361268 - 财政年份:2021
- 资助金额:
$ 111.3万 - 项目类别:
Predicting Caries Risk in Underserved Children, from Toddlers to the School-Age Years, in Primary Healthcare Settings
预测初级医疗机构中服务不足的儿童(从幼儿到学龄儿童)的龋齿风险
- 批准号:
9751077 - 财政年份:2011
- 资助金额:
$ 111.3万 - 项目类别:
Predicting Caries Risk in Underserved Children, from Toddlers to the School-Age Years, in Primary Healthcare Settings
预测初级医疗机构中服务不足的儿童(从幼儿到学龄儿童)的龋齿风险
- 批准号:
10457019 - 财政年份:2011
- 资助金额:
$ 111.3万 - 项目类别:
Predicting Caries Risk in Underserved Children, from Toddlers to the School-Age Years, in Primary Healthcare Settings
预测初级医疗机构中服务不足的儿童(从幼儿到学龄儿童)的龋齿风险
- 批准号:
9976990 - 财政年份:2011
- 资助金额:
$ 111.3万 - 项目类别:
Predicting Caries Risk in Underserved Children, from Toddlers to the School-Age Years, in Primary Healthcare Settings
预测初级医疗机构中服务不足的儿童(从幼儿到学龄儿童)的龋齿风险
- 批准号:
10213006 - 财政年份:2011
- 资助金额:
$ 111.3万 - 项目类别: